表紙
市場調查報告書
商品編碼
423719

腫瘤壞死因子受體超家族成員18:開發中產品分析

Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019

出版日期: | 出版商: Global Markets Direct | 英文 61 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以腫瘤壞死因子受體超家族成員18為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

腫瘤壞死因子受體超家族成員18 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Ablynx NV
  • Amgen Inc
  • Apogenix GmbH
  • Bristol-Myers Squibb Company
  • Five Prime Therapeutics Inc
  • Incyte Corp
  • MedImmune LLC
  • Merck & Co Inc
  • Novartis AG
  • OncoMed Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc

藥物簡介

  • AMG-228
  • BMS-986156
  • FPA-154
  • GWN-323
  • INCAGN-1876
  • LKZ-145
  • MEDI-1873
  • MK-1248
  • MK-4166
  • 免疫學·腫瘤學用GITR拮抗單株抗體
  • 惡性血液疾病·固體腫瘤GITR拮抗單株抗體
  • 腫瘤學GITR拮抗單株抗體
  • Recombinant Protein to Agonize GITR
  • TRX-518

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC1928TDB

Summary:

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 15 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5 and 3 respectively.

Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Hematological Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Colorectal Tumor, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ocular Melanoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer and Renal Cell Carcinoma.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Overview
    • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development
    • Abeome Corp
    • Ablynx NV
    • Alligator Bioscience AB
    • Apogenix AG
    • Bristol-Myers Squibb Co
    • Checkpoint Therapeutics Inc
    • GigaGen Inc
    • IGM Biosciences Inc
    • Incyte Corp
    • Leap Therapeutics Inc
    • Merck & Co Inc
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
  • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles
    • ABM-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATOR-1144 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CK-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Agonize GITR for Solid Tumor and Hematological Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWN-323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCAGN-1876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-1248 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-4166 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize GITR for Hematological Tumor and Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize GITR for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTZ-522 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-518 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Dormant Products
  • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Discontinued Products
  • Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 23, 2019: Excellent preclinical efficacy data of Apogenix' HERA-GITRL published in Journal for ImmunoTherapy of Cancer
      • Jun 04, 2019: GITR is an attractive target for immunotherapy
      • May 07, 2019: Apogenix to present its Fusion Protein to Agonize GITR for Solid Tumor at upcoming International Conference
      • Apr 02, 2019: Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
      • Dec 14, 2018: Leap therapeutics presents data on its oncology drug candidate TRX518 at ESMO Immuno-Oncology Congress 2018
      • Oct 30, 2018: Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144
      • Jan 16, 2018: Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
      • Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-518
      • Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting
      • Mar 07, 2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting
      • Mar 01, 2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting
      • Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
      • Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
      • Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
      • Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Abeome Corp, H2 2019
  • Pipeline by Ablynx NV, H2 2019
  • Pipeline by Alligator Bioscience AB, H2 2019
  • Pipeline by Apogenix AG, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Checkpoint Therapeutics Inc, H2 2019
  • Pipeline by GigaGen Inc, H2 2019
  • Pipeline by IGM Biosciences Inc, H2 2019
  • Pipeline by Incyte Corp, H2 2019
  • Pipeline by Leap Therapeutics Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019